Non-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD.
FIB-4
NAFLD
hepatocellular carcinoma
transient elastography
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
27 Apr 2022
27 Apr 2022
Historique:
received:
04
04
2022
revised:
24
04
2022
accepted:
25
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
Background: The potential role of non-invasive tests (NITs) for liver fibrosis for hepatocellular carcinoma (HCC) prediction remains poorly known. Methods: Retrospective analysis of a NAFLD cohort from a single university hospital in Barcelona, Spain. Incidence rates and cumulative incidence for the overall cohort, as well as cirrhotic and non-cirrhotic patients were calculated. Logistic regression analyses were carried out to investigate risk factors of HCC. Results: From the entire cohort of 1040 patients, 996 patients (95.8%) were analyzed, in whom 35 cases of HCC were detected, of which 26 (72.4%) HCC incident cases were newly diagnosed during a median follow-up of 2.5 (1.9−3.6) years. Two-hundred and thirty-one (23.2%) were cirrhotic at baseline. With the exception of 2 (7.7%) cases of HCC, the rest were diagnosed in cirrhotic patients. Overall HCC cumulative incidence was 9.49 (95% CI 6.4−13.9) per 1000 person-years. The incidence rate for cirrhotic patients was 41.2 (95% CI 27.6−61.6) per 1000 person-years and 0.93 (95% CI 0.23−3.7) per 1000 person-years for patients without cirrhosis. Overall mortality was significantly higher amongst patients with HCC (4.4% vs. 30.8%, p < 0.001). In patients with available liver biopsy (n = 249, 25%), advanced fibrosis (F3−F4) was significantly associated with higher HCC incidence, but not steatosis, lobular inflammation, nor ballooning. In the overall cohort, FIB-4 ≥1.3 (HR 8.46, 95% CI 1.06−67.4, p = 0.044) and older age (HR 1.06, 95% CI 1.01−1.11, p = 0.025) were associated with increasing risk of HCC over time, whereas in cirrhotic patients predictors of HCC included decreasing values of albumin (HR 0.34, 95% CI 0.13−0.87, p = 0.024), platelets (HR 0.98, 95% CI 0.98−0.99, p = 0.001), and increasing values of liver stiffness (HR 1.03, 95% CI 1.00−1.06, p = 0.016). Conclusions: In a Spanish cohort of NAFLD patients, HCC was rare in non-cirrhotic patients. NITs might play a relevant role at predicting HCC.
Identifiants
pubmed: 35566592
pii: jcm11092466
doi: 10.3390/jcm11092466
pmc: PMC9103029
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Hepatol. 2017 Nov 02;:
pubmed: 29150142
J Hepatol. 2022 Jan;76(1):247-248
pubmed: 34520785
Clin Gastroenterol Hepatol. 2022 Feb;20(2):283-292.e10
pubmed: 33965578
Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428
pubmed: 31028350
Hepatology. 2019 Jun;69(6):2672-2682
pubmed: 30179269
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
J Hepatol. 2016 Sep;65(3):570-8
pubmed: 27151181
J Clin Med. 2021 Oct 09;10(20):
pubmed: 34682759
J Hepatol. 2021 Sep;75(3):659-689
pubmed: 34166721
J Gastroenterol. 2017 Jan;52(1):104-112
pubmed: 27306373
Clin Gastroenterol Hepatol. 2022 Mar 23;:
pubmed: 35337981
Hepatol Commun. 2022 Apr;6(4):728-739
pubmed: 34783191
Clin Gastroenterol Hepatol. 2021 Apr;19(4):806-815.e5
pubmed: 32621970
Gastroenterology. 2019 May;156(6):1717-1730
pubmed: 30689971
Cancers (Basel). 2021 Sep 11;13(18):
pubmed: 34572795
PLoS One. 2018 Sep 27;13(9):e0204412
pubmed: 30260995
Hepatology. 2016 Mar;63(3):827-38
pubmed: 26599351
N Engl J Med. 2021 Oct 21;385(17):1559-1569
pubmed: 34670043
J Hepatol. 2021 Oct;75(4):786-794
pubmed: 34090928
Clin Gastroenterol Hepatol. 2022 Mar 17;:
pubmed: 35307595
Circulation. 2004 Jan 27;109(3):433-8
pubmed: 14744958
Lancet. 2018 Sep 22;392(10152):1015-1035
pubmed: 30146330
JHEP Rep. 2021 May 11;3(4):100305
pubmed: 34189448
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Liver Int. 2020 Mar;40(3):581-589
pubmed: 31749300
Medicine (Baltimore). 2021 Aug 6;100(31):e26835
pubmed: 34397849
J Hepatol. 2019 Sep;71(3):523-533
pubmed: 31145929